Dr. Adam Feng is the co-founder & Chief Scientific Officer at Zennova Pharma Group. Dr. Feng is recognized as one of the most experienced experts in pharmaceutical research & development, especially the advance technology of drug formulation & complex generic drug development. He has served as the Head of R&D in several global pharmaceutical companies.

Dr. Feng has extensive experience in pharmaceutical product development, new technology innovation, people management and project management. Since the early 1990s, he has worked in many world-renowned pharmaceutical companies including Merck, TEVA, and Takeda in the United States where he was the Director of R&D. When Dr. Feng worked as the Sr. VP and Head of Global R&D in PuraCap Pharmaceuticals, he directly managed the company's four research and development centers in US & China. Under his leadership, there were over 60 preion drugs developed in various dosage forms, including tablets, granules, soft capsules etc. It is the largest portfolio of FDA drug pipeline among all Chinese Pharmaceutical companies.

Dr. Feng has obtained more than 20 patents from US, China and globally in broad fields of drug formulation, drug analysis, process development, etc. He has a diverse and successful experience in innovative new drug (NDA) and generic drug (ANDA) development and product life cycle management expertise.

Through 26-year industry experience including senior management role, Dr. Feng has an in-depth understanding of FDA regulations, cGMP compliance and DEA (United States Drug Control Agency) compliance. Dr. Feng has led numerous new drug development projects in his previous careers. He achieved over 50 drug approval from US FDA. This accomplishment ranks him as one of the top scientist in Chinese pharmaceutical industry. Especially, two innovative new drugs NDAs (Colcrys for the treatment of gout and Fibricor for the reduction of triglycerides) were quickly reach over US$500 million in sales after they were approved and launched in US market. Dr. Feng also pioneers in complex nano-particle formulation products and multiparticulate controlled-release products.

Dr. Feng received his PhD degree in pharmaceutics from Long Island University, and his BS degree in Chemistry from Beijing Normal University. He was honored with the “3551 Leading Excellent Talent Award" in China.

Graduated from the Department of Chemistry/Natural Sciences at Akron University in the United States, with two MBA degrees from Philly Dickens University; Having 36 years of rich experience in the pharmaceutical industry and senior commercial development experience, including in the fields of raw materials, small and large molecule formulations, and generic drugs; Completed 9 company mergers and acquisitions; And has rich experience in various pharmaceutical products and ANDA cooperation and mergers and acquisitions; Participated in multiple matchmaking negotiations for startups and CDMO; Manage multiple business departments and lead multiple strategic planning processes; We have deep network relationships with pharmaceutical companies in the global market, including Europe, the United States, India, Israel, and China.

MBA from Harvard University, undergraduate degree from the University of Rochester

With more than 20 years of senior investment management experience in the financial industry, he has been responsible for more than $7 billion in financial assets and mergers and acquisitions at Merrill Lynch and Salomon Brothers (now Citibank).

He has served as CFO and director of several high-tech companies

Senior angel investor and founder of AngelVest Fund. He serves on the board of directors of the Harvard University Alumni Angel Investors Association

Professor Taft’s primary research area is pharmacokinetics, and his work involves a combination of in vitro, in vivo, and in silico techniques. Professor Taft has collaborated with numerous companies on projects ranging from characterizing renal drug excretion in rat-kidney models to drug formulation evaluation in preclinical and clinical studies. His laboratory is widely recognized for its work using isolated organ systems as tools to study drug disposition, most notably the isolated perfused kidney model. For the past several years, his research has focused on physiologically based pharmacokinetic (PBPK) modeling and simulation. Professor Taft is a member of the Editorial Advisory Boards of the Journal of Pharmaceutical Sciences (2003-present) and Drug Development and Industrial Pharmacy (2005-present). He serves on the Editorial Board for the journal Current Drug Discovery Technologies (2007-present) the AAPS Introductions to the Pharmaceutical Sciences book series. He is a past recipient of the AACP New Investigators Award, the Long Island University David Newton Award for Excellence in Teaching, the AAPS New Investigator Award in Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, and the University of Connecticut School of Pharmacy Distinguished Alumni Award. He is also an AACP Academic Leadership Fellow.

Dr. Bellantone earned a B.S. in pharmacy and a Ph.D. in physics. He has over 25 years of pharmaceutical research and development experience that integrates his diverse background in pharmacy, pharmaceutics, formulation material science, biopharmaceutics and pharmacokinetics, mathematics and numerical analysis for modeling and analyzing complex systems. He is the author or co-author of over 110 peer-reviewed research articles and presentations at national meetings and the author of a book chapter on amorphous solids. He has conducted three funded research projects for the U.S. FDA. In addition, he is the named inventor of nine awarded U.S. patents and two pending applications.